Relay Therapeutics (NASDAQ:RLAY) CFO Sells $3,176,156.11 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 187,163 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $16.97, for a total value of $3,176,156.11. Following the sale, the chief financial officer owned 177,461 shares in the company, valued at $3,011,513.17. This represents a 51.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Thomas Catinazzo also recently made the following trade(s):

• On Thursday, May 14th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $12.86, for a total value of $227,840.62.
• On Tuesday, April 28th, Thomas Catinazzo sold 972 shares of Relay Therapeutics stock. The shares were sold at an average price of $14.79, for a total value of $14,375.88.
• On Tuesday, April 7th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $13.01, for a total value of $230,498.17.
• On Thursday, April 9th, Thomas Catinazzo sold 1,800 shares of Relay Therapeutics stock. The stock was sold at an average price of $15.00, for a total value of $27,000.00.

Relay Therapeutics Trading Up 4.1%

NASDAQ:RLAY opened at $18.56 on Friday. The stock’s 50-day moving average is $14.52 and its 200-day moving average is $11.16. Relay Therapeutics, Inc. has a 1-year low of $3.03 and a 1-year high of $18.94. The stock has a market cap of $3.56 billion, a P/E ratio of -11.82 and a beta of 1.75.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The company had revenue of $3.00 million for the quarter, compared to analyst estimates of $5.58 million. As a group, equities analysts forecast that Relay Therapeutics, Inc. will post -1.55 EPS for the current year.

Wall Street Analysts Forecast Growth

RLAY has been the topic of several analyst reports. JonesTrading raised shares of Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. The Goldman Sachs Group raised their target price on Relay Therapeutics from $13.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a report on Wednesday, April 8th. Oppenheimer upped their price target on Relay Therapeutics from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Tuesday, April 28th. Finally, Wells Fargo & Company increased their price target on Relay Therapeutics from $17.00 to $21.00 and gave the company an “overweight” rating in a research note on Tuesday, April 28th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Relay Therapeutics has an average rating of “Buy” and an average price target of $23.30.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in RLAY. Seven Fleet Capital Management LP lifted its holdings in shares of Relay Therapeutics by 253.1% in the 1st quarter. Seven Fleet Capital Management LP now owns 257,738 shares of the company’s stock worth $2,564,000 after purchasing an additional 184,738 shares in the last quarter. Perceptive Advisors LLC raised its holdings in Relay Therapeutics by 412.3% during the first quarter. Perceptive Advisors LLC now owns 9,751,141 shares of the company’s stock worth $97,024,000 after buying an additional 7,847,896 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Relay Therapeutics by 86.1% in the first quarter. Bank of America Corp DE now owns 1,937,695 shares of the company’s stock valued at $19,280,000 after buying an additional 896,746 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Relay Therapeutics by 77.8% in the first quarter. Janus Henderson Group PLC now owns 65,573 shares of the company’s stock valued at $652,000 after buying an additional 28,700 shares in the last quarter. Finally, Amundi acquired a new position in shares of Relay Therapeutics during the first quarter valued at about $213,000. Institutional investors own 96.98% of the company’s stock.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.